Multi-center, parallel-group, open-label, randomized, comparative study in patients with tachyarrhythmia in sepsis versus those untreated (J-Land 3S study)

Status: Not yet recruiting

Phase of Trial: Phase II/III

Latest Information Update: 07 Dec 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Jun 2020 Results presented in an Ono Pharmaceutical Media Release.
29 Jun 2020 According to an Ono Pharmaceutical media release, the results of this study are published in The LANCET Respiratory Medicine.
29 Jun 2020 According to an Ono Pharmaceutical media release, company received an approval of Onoact for Intravenous Infusion 50mg/150mg for additional indication of tachyarrhythmia (atrial fibrillation, atrial flutter and sinus tachycardia) associated with sepsis for a partial change in the approved items of the manufacturing and marketing approval in Japan.This approval is based on the result of this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com